Keyword: Insys Therapeutics
When Insys settled with the feds for $225 million, the drugmaker hoped it had put its troubled past behind it. Now they’re filing for bankruptcy.
After federal prosecutors bagged multiple former execs, Insys had to know its day of reckoning was near. Now it's here—and it'll cost $225 million.
Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.
Insys founder John Kapoor was found guilty on federal racketeering charges in a landmark case nailing C-level executives in the U.S. opioid epidemic.
Insys CEO Saeed Mohatari is making a quick exit—and CFO Andrew Long will take his place—as the company aims to revamp its business and its rep.
Insys’ former VP of sales has turned state's evidence in an Arizona kickback suit alleging company executives drove a scheme to buy Subsys scripts.
In an Insys Therapeutics case that’s already full of shocking details, prosecutors just upped the ante.
During Insys founder John Kapoor's criminal trial, prosecutors played a video urging sales reps to break the rules when promoting its opioid Subsys.
The U.S. Senate has released a report on Insys that provides an insider’s view of a company leaning on physicians to help drive sales.
The $150 million is in line with Insys' previous estimate, and the final deal could include contingency-based payments of up to $75 million.